{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:20Z","timestamp":1791994580653,"version":"4.4.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bullous pemphigoid (BP) affects elderly individuals with multiple comorbidities, making conventional treatments unsuitable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Evaluate the effectiveness and safety of dupilumab in the treatment of BP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre ambispective cohort study was conducted across 34 hospitals. Patients with BP treated with dupilumab were included. Most of the patients (97.1%) received an initial 600-mg dose followed by 300\u2005mg every 2 weeks. The primary outcome was the proportion of patients achieving complete remission (CR) within 4 weeks, defined as an Investigator\u2019s Global Assessment score of 0 or 1. CR at weeks 16, 24 and 52, adverse events (AEs), reductions in Peak Pruritus Numerical Rating Scale (PP-NRS) and systemic glucocorticoid use were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 103 patients with a median age of 77.3\u2005years; 58.3% were male. CR was achieved by 53.4% within 4 weeks and 95.7% by week 52. The PP-NRS score reduced by 70.0% by week 4 and was completely controlled by week 24. Thirteen patients presented with AEs, most of which were mild. Systemic glucocorticoid use reduced by 82.1% by week 52. Shorter disease duration and exclusive cutaneous involvement predicted better response at 16 weeks. No differences in response rates to dupilumab were observed between drug-associated BP and idiopathic cases. No significant difference in response rates was observed between patients treated with dupilumab in monotherapy and those receiving dupilumab with concomitant treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dupilumab is effective, rapid and safe in managing BP, reducing the need for corticosteroids and other treatments. Early initiation and exclusive skin involvement predict better outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae403","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T07:27:16Z","timestamp":1729063636000},"page":"501-509","source":"Crossref","is-referenced-by-count":39,"title":["Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1303-2422","authenticated-orcid":false,"given":"Nidia","family":"Planella-Fontanillas","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bosch-Amate","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Cl\u00ednic de Barcelona, University of Barcelona , IDIBAPS, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Jim\u00e9nez Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Moreno-V\u00edlchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Gamo","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Mar","family":"Blanes Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda\u00a0Asunci\u00f3n","family":"Ballester Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bassas-Freixas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-1078","authenticated-orcid":false,"given":"Juan Luis","family":"Casta\u00f1o Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Est\u00e9banez Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Suarez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Santos Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bauz\u00e1","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Torrent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Ballano Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Collantes Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Espa\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Fonseca Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada Gil","family":"Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos\u00a0Pelayo","family":"Hern\u00e1ndez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-6727","authenticated-orcid":false,"given":"Francisco Javier","family":"Melgosa Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Spertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Zaragoza Ninet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Armillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Bielsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Cl\u00ednic de Barcelona, University of Barcelona , IDIBAPS, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Esquius Rafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Fulgencio Barbarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fernandez Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Lova Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Mart\u00edn Callizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mart\u00edn-Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisabet Parera","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S\u00e1nchez","family":"Puigdollers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon M","family":"Pujol","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Podlipnik","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Cl\u00ednic de Barcelona, University of Barcelona , IDIBAPS, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Jos\u00e9 Manuel","family":"Mascar\u00f3","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Cl\u00ednic de Barcelona, University of Barcelona , IDIBAPS, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Curto-Barredo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"2025021810042006100_ljae403-B1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"2025021810042006100_ljae403-B2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2025021810042006100_ljae403-B3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2025021810042006100_ljae403-B4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2\u2005K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2025021810042006100_ljae403-B5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: a systematic review and meta-analysis","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025021810042006100_ljae403-B6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"2025021810042006100_ljae403-B7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdin.2022.07.005","article-title":"Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: a systematic review","volume":"9","author":"Zeng","year":"2022","journal-title":"JAAD Int"},{"key":"2025021810042006100_ljae403-B8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5694\/j.1326-5377.1986.tb112242.x","article-title":"Side-effects of corticosteroid agents","volume":"144","author":"Seale","year":"1986","journal-title":"Med J Aust"},{"key":"2025021810042006100_ljae403-B9","doi-asserted-by":"crossref","first-page":"1057096","DOI":"10.3389\/fmed.2022.1057096","article-title":"Bullous pemphigoid \u2013 what do we know about the most recent therapies?","volume":"9","author":"Zeng","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025021810042006100_ljae403-B10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"key":"2025021810042006100_ljae403-B11","doi-asserted-by":"crossref","first-page":"611549","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid","volume":"11","author":"Seyed Jafari","year":"2020","journal-title":"Front Immunol"},{"key":"2025021810042006100_ljae403-B12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025021810042006100_ljae403-B13","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv Ther"},{"key":"2025021810042006100_ljae403-B14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025021810042006100_ljae403-B15","article-title":"Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature","volume":"27","author":"Saleh","year":"2021","journal-title":"Dermatol Online J"},{"key":"2025021810042006100_ljae403-B16","doi-asserted-by":"crossref","first-page":"738907","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2025021810042006100_ljae403-B17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025021810042006100_ljae403-B18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/bjd\/ljad136","article-title":"Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients","volume":"189","author":"Moghadam","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025021810042006100_ljae403-B19","doi-asserted-by":"crossref","first-page":"111157","DOI":"10.1016\/j.intimp.2023.111157","article-title":"Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study","volume":"125","author":"Huang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2025021810042006100_ljae403-B20","doi-asserted-by":"crossref","first-page":"e13488","DOI":"10.1111\/srt.13488","article-title":"Effectiveness and safety of dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid","volume":"29","author":"Manzo Margiotta","year":"2023","journal-title":"Skin Res Technol"},{"key":"2025021810042006100_ljae403-B21","doi-asserted-by":"crossref","first-page":"1165106","DOI":"10.3389\/fimmu.2023.1165106","article-title":"Anti-interleukin 4 receptor \u03b1 antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"2025021810042006100_ljae403-B22","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1002\/iid3.924","article-title":"Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: a preliminary study","volume":"11","author":"Hu","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"2025021810042006100_ljae403-B23","doi-asserted-by":"crossref","first-page":"1243581","DOI":"10.3389\/fimmu.2023.1243581","article-title":"Precision in treatment evaluation: importance of minimal clinically important differences (MCIDs) of outcome measures for autoimmune blistering diseases","volume":"14","author":"Tseng","year":"2023","journal-title":"Front Immunol"},{"key":"2025021810042006100_ljae403-B24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/ds.DS-D-22-00150","article-title":"Pemphigus scoring systems and their validation studies \u2013 a review of the literature","volume":"41","author":"Boucher","year":"2023","journal-title":"Dermatologica Sinica"},{"key":"2025021810042006100_ljae403-B25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2025021810042006100_ljae403-B26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.09.014","article-title":"Nonbullous erythrodermic pemphigoid with florid lymphadenopathy, response to dupilumab","volume":"17","author":"Bal","year":"2021","journal-title":"JAAD Case Rep"},{"key":"2025021810042006100_ljae403-B27","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1111\/jdv.17999","article-title":"Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study","volume":"36","author":"Velin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025021810042006100_ljae403-B28","doi-asserted-by":"crossref","first-page":"e15727","DOI":"10.1111\/dth.15727","article-title":"Severe pemphigoid nodularis successfully treated with dupilumab","volume":"35","author":"Jendoubi","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025021810042006100_ljae403-B29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1684\/ejd.2021.4190","article-title":"Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients","volume":"31","author":"Liu","year":"2021","journal-title":"Eur J Dermatol"},{"key":"2025021810042006100_ljae403-B30","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1111\/ijd.16451","article-title":"Successful treatment of eczema-like bullous pemphigoid and typical bullous pemphigoid with dupilumab: two case reports","volume":"62","author":"Xu","year":"2023","journal-title":"Int J Dermatol"},{"key":"2025021810042006100_ljae403-B31","doi-asserted-by":"publisher","DOI":"10.5070\/D328257396","article-title":"A case of nivolumab\u200b-induced bullous pemphigoid successfully treated with dupilumab","volume":"28","author":"Bruni","year":"2022","journal-title":"Dermatol Online J"},{"key":"2025021810042006100_ljae403-B32","doi-asserted-by":"crossref","first-page":"e15648","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025021810042006100_ljae403-B33","author":"Sanofi Press Release"},{"key":"2025021810042006100_ljae403-B34","doi-asserted-by":"crossref","first-page":"928621","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"2025021810042006100_ljae403-B35","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/ced\/llae067","article-title":"Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience","volume":"49","author":"Aguado V\u00e1zquez","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2025021810042006100_ljae403-B36","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid","volume":"161","author":"G\u00fcrcan","year":"2009","journal-title":"Br J Dermatol"},{"key":"2025021810042006100_ljae403-B37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0190-9622(96)80085-5","article-title":"Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases","volume":"34","author":"Bouscarat","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2025021810042006100_ljae403-B38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaad.2018.07.048","article-title":"Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"80","author":"Blauvelt","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025021810042006100_ljae403-B39","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"2025021810042006100_ljae403-B40","doi-asserted-by":"crossref","first-page":"adv00224","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-induced pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025021810042006100_ljae403-B41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae403\/60933754\/ljae403.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/3\/501\/60933754\/ljae403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/3\/501\/60933754\/ljae403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:04:44Z","timestamp":1739855084000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/3\/501\/7824844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,17]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae403","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,17]]}}}